Navigation Links
AlphaVax Announces New CMV Advisory Board
Date:1/30/2008

RESEARCH TRIANGLE PARK, N.C., Jan. 30 /PRNewswire/ -- AlphaVax has assembled its Cytomegalovirus (CMV) Advisory Board to provide expertise and advice as the company moves its CMV vaccine candidates through clinical development. To be chaired by Dr. Robert Olmsted, AlphaVax's Vice President for Research, the Board members include:

-- Mark Schleiss, MD, Professor, Associate Head for Research and the

American Legion Chair in the Department of Pediatrics and Director,

Division of Infectious Diseases, at the University of Minnesota.

-- David Bernstein, MD, Albert Sabin Professor of Pediatrics, Director,

Infectious Diseases and Director of the Gamble Program at the

Cincinnati Children's Hospital and Medical Center.

-- Robert Pass, MD, Professor, Pediatrics and Microbiology at the

University of Alabama - Birmingham.

-- Paul D. Griffiths, MD, DSc, Professor and Head of the Centre for

Virology, Division of Infection at Royal Free and University College

Medical School in London.

AlphaVax is pleased to have these distinguished researchers and clinicians in the field of cytomegalovirus provide their perspectives on advancing an alphavirus vectored CMV vaccine. "We look forward to working with our CMV Advisory Board to help design and implement post-Phase I clinical programs for assessing the potential of our CMV vaccine candidates in transplant indications, prevention of mother-to-child transmission, and prophylactic adolescent immunization," said Dr. Olmsted.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. In addition to programs in influenza and cytomegalovirus, important disease targets include cancer, HIV and a number of biodefense vaccine products. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
2. ADVENTRX Announces Consolidation of Clinical and Management Positions
3. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
4. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
5. BD Announces Results of Shareholder Votes at Annual Meeting
6. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
7. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
8. Sunnylife Global Announces Completion of Surgical Wing of Xiang Tan World Friendship Hospital
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/9/2017)... , Australia , March 9, 2017 ... data at the prestigious World Lung Imaging Workshop at ... Andreas Fouras , was invited to deliver the latest ... medicine. This globally recognised event brings together leaders at ... the latest developments in lung imaging. ...
Breaking Biology News(10 mins):